Abstract
While levodopa therapy for Parkinson's disease is still considered the gold standard, motor complications are significant disadvantages of treatment. Monotherapy with dopamine agonists may present an alternative approach with a reduced likelihood of developing dyskinesias. Further studies are required before a definitive judgment can be made.
Original language | English |
---|---|
Pages (from-to) | 8-11 |
Number of pages | 4 |
Journal | Hospital Medicine |
Volume | 64 |
Publication status | Published - 1 Jan 2003 |